Living with Hepatitis C: Qualitative Interviews with Hepatitis C-infected Veterans

  • Erik J. Groessl
  • Kimberly R. Weingart
  • Robert M. Kaplan
  • Jack A. Clark
  • Allen L. Gifford
  • Samuel B. Ho
Original Article



Chronic hepatitis C (HCV) infection affects millions of people in the USA and prevalence rates are higher in US veterans. The consequences of HCV infection include reduced quality of life, liver damage, and reduced longevity.


Our objective was to describe the experiences of US veterans living with chronic HCV infection and use this information in the development of an HCV self-management intervention.


Twenty-two male HCV-infected veterans completed qualitative interviews. Participants were recruited via flyers and hepatitis C clinic providers at a major VA medical center. Participants were asked about their medical history, being diagnosed with HCV, and general experiences living with HCV.


The study gathered the following findings: the impact of HCV on interpersonal relationships was pronounced, recovery from substance use disorders and getting care for HCV were connected, receiving the HCV diagnosis was more troubling to non-IV drug users, participants had misconceptions about HCV and its treatment, psychological problems were prevalent as were barriers to participating in antiviral treatment and HCV care in general.


The themes derived from our analysis indicate that affected veterans may benefit from interventions or support to improve HCV-related health education, social/relationship issues, psychological issues, and exploration of the connection between substance use recovery and motivation to get care for HCV infection.


hepatitis C HCV veterans treatment impact 



Dr. Groessl’s work on this study was funded by a VA HSR&D Merit Review Entry Program Award #03–327 and VA HSRD IIR # IAC 05–067.

Conflict of Interest

None disclosed.


  1. 1.
    Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325(2):98–104. Jul 11PubMedGoogle Scholar
  2. 2.
    Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639–644. MarPubMedGoogle Scholar
  3. 3.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556–562. Aug 19PubMedCrossRefGoogle Scholar
  4. 4.
    Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41(1):88–96. JanPubMedCrossRefGoogle Scholar
  5. 5.
    Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997;26(3):521–526. SepPubMedCrossRefGoogle Scholar
  6. 6.
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562–1569. OctPubMedCrossRefGoogle Scholar
  7. 7.
    Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42(12):2482–2486. DecPubMedCrossRefGoogle Scholar
  8. 8.
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27(1):209–212. JanPubMedCrossRefGoogle Scholar
  9. 9.
    Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–1301. NovPubMedCrossRefGoogle Scholar
  10. 10.
    Glacken M, Kernohan G, Coates V. Diagnosed with Hepatitis C: a descriptive exploratory study. Int J Nurs Stud. 2001;38(1):107–116. FebPubMedCrossRefGoogle Scholar
  11. 11.
    Gifford SM, O’Brien ML, Bammer G, Banwell C, Stoove M. Australian women’s experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol. 2003;18(7):841–850. JulPubMedCrossRefGoogle Scholar
  12. 12.
    Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. 2007;6(4):169–175.Google Scholar
  13. 13.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. Sep 22PubMedCrossRefGoogle Scholar
  14. 14.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. Sep 26PubMedCrossRefGoogle Scholar
  15. 15.
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355. Mar 2PubMedGoogle Scholar
  16. 16.
    Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56(3):385–389. MarPubMedCrossRefGoogle Scholar
  17. 17.
    National Institutes of Health. Management of Hepatitis C:2002 June 10–12, 2002 2002.Google Scholar
  18. 18.
    VA National Hepatitis C Program. VA Treatment Recommendations - Patients with Chronic Hepatitis C (Version 5.0). Federal Practitioner. September 2003;20(Suppl. 5).Google Scholar
  19. 19.
    Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: Effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262.PubMedCrossRefGoogle Scholar
  20. 20.
    Cronan TA, Groessl E, Kaplan RM. The effects of social support and education interventions on health care costs. Arthritis Care Res. 1997;10(2):99–110. AprPubMedCrossRefGoogle Scholar
  21. 21.
    Lorig KR, Ritter P, Stewart AL, et al. Chronic disease self-management program: 2-year health status and health care utilization outcomes. Med Care. 2001;39(11):1217–1223. NovPubMedCrossRefGoogle Scholar
  22. 22.
    Lorig KR, Ritter PL, Gonzalez VM. Hispanic chronic disease self-management: a randomized community-based outcome trial. Nurs Res. 2003;52(6):361–369. Nov-DecPubMedCrossRefGoogle Scholar
  23. 23.
    Groessl EJ, Cronan TA. A cost analysis of self-management programs for people with chronic illness. Am J Community Psychol. 2000;28(4):455–480. AugPubMedCrossRefGoogle Scholar
  24. 24.
    Cronan TA, Hay M, Groessl E, Bigatti S, Gallagher R, Tomita M. The effects of social support and education on health care costs after three years. Arthritis Care Res. 1998;11(5):326–334. OctPubMedCrossRefGoogle Scholar
  25. 25.
    Sankar A, Golin C, Simoni JM, Luborsky M, Pearson C. How qualitative methods contribute to understanding combination antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S54–68. Dec 1PubMedGoogle Scholar
  26. 26.
    Crockett B, Gifford SM. “Eyes Wide Shut”: narratives of women living with hepatitis C in Australia. Women Health. 2004;39(4):117–137.PubMedCrossRefGoogle Scholar
  27. 27.
    Glacken M, Coates V, Kernohan G, Hegarty J. The experience of fatigue for people living with hepatitis C. J Clin Nurs. 2003;12(2):244–252. MarPubMedGoogle Scholar
  28. 28.
    Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol. 2006;12(29):4665–4672. Aug 7PubMedGoogle Scholar
  29. 29.
    Zickmund S, Hi EY, Masuda M, Ippolito L, LaBrecque DR. “They treat me like a leper” Stigatization and the quality of life of patients with hepatitis C. J Gen Intern Med. 2003;18:835–844.PubMedCrossRefGoogle Scholar
  30. 30.
    Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology. 2004;39(4):999–1007. AprPubMedCrossRefGoogle Scholar
  31. 31.
    Centers for Disease Control and Prevention. Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report. 1998;47:1–39.Google Scholar
  32. 32.
    Davis M, Rhodes T, Martin A. Preventing hepatitis C: ‘common sense’, ‘the bug’ and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004;59(9):1807–1818. NovPubMedCrossRefGoogle Scholar
  33. 33.
    Rhodes T, Davis M, Judd A. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction. 2004;99(5):621–633. MayPubMedCrossRefGoogle Scholar
  34. 34.
    Tompkins CN, Wright NM, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract. 2005;55(513):263–268. AprPubMedGoogle Scholar
  35. 35.
    Cullen W, Kelly Y, Stanley J, Langton D, Bury G. Experience of hepatitis C among current or former heroin users attending general practice. Ir Med J. 2005;98(3):73–74. MarPubMedGoogle Scholar
  36. 36.
    Hopwood M, Treloar C. The experience of interferon-based treatments for hepatitis C infection. Qual Health Res. 2005;15(5):635–646. MayPubMedCrossRefGoogle Scholar
  37. 37.
    Sheppard K, Hubbert A. The patient experience of treatment for hepatitis C. Gastroenterol Nurs. 2006;29(4):309–315. Jul-AugPubMedCrossRefGoogle Scholar
  38. 38.
    Kaplan R, Anderson J. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven; 1996: 309–322.Google Scholar
  39. 39.
    Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1982;1:61–80.CrossRefGoogle Scholar
  40. 40.
    Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res. 1976;11(4):478–507. WinterPubMedGoogle Scholar
  41. 41.
    Dollarhide AW, Groessl EJ, Ho SB. Determining current barriers to antiviral treatment in a cohort of U.S. veterans referred for HCV evaluation. Paper presented at: J Hepatology 2007.Google Scholar
  42. 42.
    Sloan KL, Straits-Troster KA, Dominitz JA, Kivlahan DR. Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest. J Clin Gastroenterol. 2004;38(3):279–284. MarPubMedCrossRefGoogle Scholar
  43. 43.
    VA National Hepatitis C Program Patients and Public Information. Internet]. June 18, 2007; Accessed 08/28/2008.
  44. 44.
    Roselle GA, Danko LH, Kralovic SM, Simbartl LA, Kizer KW. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med. 2002;167(9):756–759. SepPubMedGoogle Scholar
  45. 45.
    Groessl EJ, Weingart KR, Kaplan RM, Ho SB. Health-Related Quality of Life in HCV Infected Patients. Current Hepatitis Reports. in press.Google Scholar
  46. 46.
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800. AprPubMedCrossRefGoogle Scholar
  47. 47.
    Strauss E, Dias Teixeira MC. Quality of life in hepatitis C. Liver Int. 2006;26(7):755–765. SepPubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2008

Authors and Affiliations

  • Erik J. Groessl
    • 1
    • 2
  • Kimberly R. Weingart
    • 1
  • Robert M. Kaplan
    • 3
  • Jack A. Clark
    • 4
    • 5
  • Allen L. Gifford
    • 4
    • 5
  • Samuel B. Ho
    • 1
    • 2
  1. 1.Health Services Research and DevelopmentVA San Diego Healthcare SystemSan DiegoUSA
  2. 2.University of California San DiegoSan DiegoUSA
  3. 3.School of Public HealthUniversity of California Los AngelesLos AngelesUSA
  4. 4.Boston University School of Public HealthBostonUSA
  5. 5.Edith Nourse Rogers Memorial Veterans HospitalBedfordUSA

Personalised recommendations